Alamar Biosciences and several research universities have launched a national initiative to identify blood-based biomarkers for Alzheimer’s disease and related neurodegenerative conditions [1].
This effort represents a shift toward non-invasive diagnostics for dementia. By identifying specific protein patterns in the blood, researchers hope to detect cognitive decline earlier and more accurately than current methods allow.
The project leverages the National Alzheimer’s Coordinating Center network in the U.S. to profile approximately 21,000 plasma samples [1]. These samples come from 10,000 participants living with Alzheimer’s disease and related dementias [1].
To analyze these samples, the initiative uses the NULISAseq™ Neuro 220 proteomics panel [2]. This technology allows researchers to map protein expressions that may serve as early warning signs for the disease.
A primary goal of the partnership is to create a dataset that remains publicly accessible [1]. This openness is intended to fuel AI-driven research, allowing scientists worldwide to use machine learning to find new patterns in the proteomics data [1].
The collaboration between the private company and academic institutions aims to accelerate the validation of these biomarkers. Validated blood tests could eventually replace more invasive or expensive diagnostic tools, such as cerebrospinal fluid draws or PET scans, in clinical settings [1].
“The project leverages the National Alzheimer’s Coordinating Center network in the U.S.”
The scale of this initiative, involving 10,000 participants, provides a massive data foundation for the next generation of diagnostic AI. By moving toward blood-based biomarkers, the medical community moves closer to routine screening for Alzheimer's, which could allow for therapeutic interventions to begin years before severe symptoms appear.
